SUMMARY
Bovine pericardial patches have become increasingly popular for carotid repair thanks to their advantages over synthetic patches, including superior bio-compatibility, reduced suture bleeding and better surgical handling, without restrictions on ultrasound tests. However, until now, biomaterials have been linked to problems including toxicity, immune reactions and calcification. Engineered using APADT® technology, the VascuCel® bio-scaffold provides the benefits of a biopatch while avoiding the trade-offs: ADAPT® scaffolds are completely acellular, thoroughly crosslinked and fully detoxified and sterilised, providing healing through new tissue growth, minimised risk of re-operation for the patient, and an optimised procedure for the surgeon.
http://www.admedus.com/wp-content/u.../Admedus-VascuCel-review-Nov-2016-final-1.pdf
Edit: Mods please correct title to VascuCel - a typo!
VacuCel Clinical Literature Review
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |